G protein-coupled receptors (GPCRs) represent the largest family of proteins targeted by drug
design and discovery efforts. Of these efforts, the development of GPCR agonists is highly desirable,
due to their therapeutic robust utility in treating diseases caused by deficient receptor signaling. One of
the challenges in designing potent and selective GPCR agonists lies in the inability to achieve combined
high binding affinity and subtype selectivity, due to the high homology between orthosteric sites among
GPCR subtypes. To combat this difficulty, researchers have begun to explore the utility of targeting topographically
distinct and less conserved binding sites, namely “allosteric” sites. Pursuing these sites
offers the benefit of achieving high subtype selectivity, however, it also can result in a decreased binding
affinity and potency as compared to orthosteric agonists. Therefore, bitopic ligands comprised of an orthosteric
agonist and an allosteric modulator connected by a spacer and allowing binding with both the
orthosteric and allosteric sites within one receptor, have been developed. It may combine the high subtype
selectivity of an allosteric modulator with the high binding affinity of an orthosteric agonist and
provides desired advantages over orthosteric agonists or allosteric modulators alone. Herein, we review
the recent advances in the development of bitopic agonists/activators for various GPCR targets and their
novel therapeutic potentials.
A bivalent compound 1a featuring both a mu opioid receptor (MOR) and a CXCR4 antagonist pharmacophore (naltrexone and IT1t) was designed and synthesized. Further binding and functional studies demonstrated 1a acting as a MOR and a CXCR4 dual antagonist with reasonable binding affinities at both receptors. Furthermore, compound 1a seemed more effective than a combination of IT1t and naltrexone in inhibiting HIV entry at the presence of morphine. Additional molecular modeling results suggested that 1a may bind with the putative MOR-CXCR4 heterodimer to induce its anti-HIV activity. Collectively, bivalent ligand 1a may serve as a promising lead to develop chemical probes targeting the putative MOR-CXCR4 heterodimer in comprehending opioid exacerbated HIV-1 invasion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.